Theranostix.io
Strategic intelligence for theranostics leaders

See the theranostics market
before it becomes obvious.

Theranostix converts registry data, clinical maturity, target density, centre activity and preclinical signals into a single decision layer for pharma, biotech, investors and clinical strategy teams.

Explore the platformAIDiscover our AI scoring models
>350published clinical trials
>40countries covered through trial sites
>130distinct molecules tracked
>30known biotech companies in preclinical research
PSMA SSTR2 CXCR4 GRPR WHITE-SPACE FAP · emerging low competition SCAN 130+ COMPETITIVE DENSITY crowded → open MATURITY
Proprietary AI scoring

Two models turn theranostic complexity into clear next steps.

Discover our two proprietary AI models: one ranks the most active medical centres in theranostics by country; the other maps competitive density across the focused theranostics field, so teams can instantly spot crowded spaces, emerging races and open development opportunities.

AI Activity Rank Scoring

Centre Activity Ranking System

Ranks medical centres by country by combining curated site consolidation, trial participation, target breadth and recency signals.

  • Highlights the most active centres for each geography
  • Reduces noise from duplicated or inconsistent site names
  • Supports country-by-country BD, KOL and launch planning
Competitive Density Scoring System

Competitive Density Intelligence Engine

Positions each target, sponsor and programme in the narrow theranostics domain to reveal where the market is crowded, emerging or still white-space.

  • Separates crowded leaders from focused niches
  • Detects emerging targets before they look obvious
  • Turns density, maturity and momentum into BD signals

Both proprietary scoring systems are refreshed monthly to reflect the most accurate and up-to-date view of the global theranostics landscape.

Interactive product tour

Nine modules, one intelligence layer.

Click a module to switch the preview. The product is explained through real dashboard evidence across nine strategic views.

Dashboard module preview
Live product view

Global Clinical Trials List product preview with smart filtering, global activity map and centre ranking callouts
Dashboard evidence

Real product screens, different decision angles.

The landing page can rotate between landscape, pipeline, maturity and competitive-density evidence so visitors immediately understand the breadth of the platform.

Global landscape dashboard

Global theranostic activity

Country-level map, registry trial list, filters and strategic alert zone.

Pipeline cards dashboard

Pipeline cards

Trial cards by target and maturity, ready for rapid scanning.

Competitive density dashboard

Competitive density

Targets ranked by activity, sponsor load, maturity and opportunity signal.

Make theranostic development easier to read.

Use one premium intelligence layer to follow targets, centres, sponsors, maturity and business-development opportunity signals.

Request a demo
Benefits

Strategic clarityfor every theranostics decision-maker.

Theranostix is designed for teams that need to move faster in a fragmented, fast-growing field. It turns trial registries, sponsor activity, centre expertise, maturity signals and AI-scored competitive density into practical decisions.

✓
For pipeline decisions: understand whether a target is crowded, emerging or still defensible.
✓
For clinical execution: identify the most relevant countries, centres and trial networks.
✓
For strategic conversations: support BD, investor and partnership discussions with evidence.
Site selection

From a world map to a contact file, in three steps.

The question a radioligand programme has to answer is not « where is oncology research happening ». It is which centres are genuinely the most active on your target, which of them can handle your isotope, and who to write to on Monday morning.

Centre coverage
37Countries mapped
467Canonical trial centres
1,862Centre locations
1,774Trial-linked locations
1

See the most active centres, country by country

Every named centre with public theranostic trial activity, plotted worldwide and ranked by an AI-curated activity score. Canonical centres and unresolved registry locations are shown side by side, marked differently — never silently merged.

Activity score curated per centre, not per country
City-level clustering with exonym resolution
Filter by target, isotope, phase and status
2

Compare centres side by side

Up to five centres on a shared timeline. Trial counts, sponsors, phases, declared capabilities and contactability — each one traceable to the record it came from, so a feasibility shortlist can be defended rather than asserted.

Shared year axis, so activity is comparable
Declared / inferred / absent, never averaged into a score
Export the comparison to CSV, 21 columns
3

Reach the investigators who can run it

A contact file with one row per person, their role exactly as published by the registry, and the trials they are attached to. Compose a structured feasibility enquiry and export it as a draft — you keep ownership of the relationship.

2,091 named contacts · 952 emails · 899 phones
Principal investigators identified where the sponsor named one
Draft exports as .eml, .txt or clipboard
Site selection — global map of theranostic trial centres by country
Step 1 — map sites Country ranking, live registry activity and centre coverage in a single view. Every figure is computed from the current snapshot. Real product screen
Site selection — comparison of selected centres with capabilities and investigators
Steps 2 & 3 — compare and contact Capabilities, trial history and named investigators for each shortlisted centre, ready to be exported into a contact file. Real product screen
B

For biotech companies

Small biotech teams often need to defend a target, select countries, choose centres and explain their positioning before they have large internal strategy teams. Theranostix helps them benchmark their programme against visible competitors, detect crowded or underserved spaces and prepare stronger investor or BD discussions with registry-backed evidence.

1

Benchmark your target against active theranostic competitors.

2

Prioritize countries and centres before launching or expanding a trial.

3

Identify white-space opportunities for pipeline expansion.

4

Support investor positioning with concrete market evidence.

Best suited for early-stage companies, clinical-stage biotechs, radiopharmaceutical innovators and teams preparing fundraising, partnering or trial expansion.
P

For pharma teams

Pharma and BD teams need to understand who is active, where sponsor concentration is rising and which targets are becoming strategically crowded. Theranostix brings together sponsor dynamics, target maturity, centre activity and competitive-density signals to help teams screen opportunities, compare assets and identify potential partners earlier.

1

Map sponsor activity across targets, phases and geographies.

2

Detect emerging companies before they become late-stage competitors.

3

Compare target maturity and competitive pressure across the field.

4

Support licensing, acquisition and co-development screening.

Useful for BD, medical strategy, portfolio teams, external innovation groups and launch-planning teams following the radiopharmaceutical market.
I

For investors

Investors need to evaluate whether a theranostic asset is differentiated, crowded, underdeveloped or strategically attractive. Theranostix helps accelerate diligence by showing target density, sponsor concentration, centre activity, preclinical signals and development maturity in a clear, evidence-based format.

1

Assess target defensibility and market saturation.

2

Validate biotech claims against public registry-backed evidence.

3

Identify emerging areas before they appear in mainstream reports.

4

Build faster investment memos around opportunity and risk.

Designed for venture investors, strategic investors, corporate development teams and analysts evaluating radiopharmaceutical assets.
The evidence base

Depth in one modality beats breadth across forty.

A generalist platform records that a trial uses a drug. We record that it uses ¹⁷⁷Lu bound to a PSMA ligand, paired with a ⁶⁸Ga diagnostic, at a centre with an on-premises hot lab. Every figure below is computed from the live snapshot, not from a marketing round-up.

638Trials indexed
427Core therapeutic RLT
256Recruiting now
46Countries
2,091Named site contacts
130+Molecules tracked
Sources ClinicalTrials.gov + CTIS / EU CTR + sponsor filings — reconciled, de-duplicated across registries and curated by hand where registries disagree. Trials are classified into eight scopes, so nothing sits in an unlabelled bucket.
Methodology

Facts you can check, not a number you have to trust.

Every capability of every centre is exactly one of three things, and the interface always says which. Nothing is smoothed into a percentage, and nothing is guessed.

✓
Declared — stated by the centre or present in a registry field.
~
Inferred — deduced from trial history, and labelled as such wherever it appears.
·
Absent — we hold no record. That is not the same as « no ».

The same rule governs people. A contact published as a registry contact is never relabelled « Principal Investigator » because it would read better. If the sponsor named nobody, we print that the sponsor named nobody.

Scope

What we deliberately do not do.

Publishing our limits is how the rest of the platform becomes credible. Every line below is a decision, not a gap we are waiting to close.

  • No composite site-fit score. A site that scores 78 out of 100 cannot be defended in a governance meeting.
  • No patient-level data, and no ambition to hold any.
  • No coverage outside theranostics. We are not a general pharma database.
  • No invented contacts and no inferred job titles.
  • No emails sent on your behalf. We prepare the draft — you keep the relationship.
  • No hidden gaps. A missing field is displayed as missing.
Why not a generalist platform

The questions that decide a radioligand programme.

Broad trial-intelligence suites answer the first question well. It is the four that follow which determine whether a study opens on time — and they are the ones no generalist database models.

Question
Generalist trial intelligence
Theranostix
Which isotope does this trial use?
Buried in the drug name, if recorded at all
A structured field, kept separate from the ligand
Which diagnostic selects patients for this therapy?
Not modelled
Theranostic pairing is a first-class relation — 33 pairs indexed
Can this centre actually handle Ac‑225?
The site has run oncology trials
Radiopharmacy capability per centre, declared or inferred
Why is this centre ranked above that one?
A proprietary composite score
No ranking — a comparison of stated facts, each traceable
What is missing from your data?
Rarely published
Listed above, and shown per record inside the product

Turn market complexity into a sharper strategic story.

Request a demo and we will focus the walkthrough on your target, geography, sponsor landscape or investment question.

Request a demo →
Solutions

One Platform. Every signal.
The full theranostics picture.

Theranostix offers several integrated solutions to help biotech companies, pharmaceutical companies and other industrial actors understand the complexity of the theranostics landscape through advanced analytics modules and our latest AI scoring systems.

✓Clinical-trial list updated weekly ✦AI scores recalculated monthly ⌁Registry-backed evidence
Explore our modules

Nine modules, one intelligence layer.

Each module turns a different part of the theranostics ecosystem into a clear operational view: trials, molecules, centres, timelines, maturity, sponsors, opportunity and competitive density.

01
Module 01

Global Clinical Trials List

Global Clinical Trials List preview

Monitor the worldwide theranostics clinical-trial universe with weekly updates and structured filters.

From registry noise to a usable global trial universe.

This module consolidates published theranostic trials into a structured, searchable view. Teams can filter by target, isotope, sponsor, phase, recruitment status, country and pathology, then quickly identify where clinical development is active or still under-represented.

  • Weekly clinical-trial refresh
  • Target, sponsor and phase filters
  • Built for rapid landscape review
02
Module 02

Preclinical Molecule Explorer

Preclinical Molecule Explorer preview

Follow preclinical and transition-stage molecules, targets and early development signals before they become visible clinically.

Capture early molecules before they appear as mature clinical competitors.

The preclinical view highlights molecules and programmes that are still in laboratory, transition or early development. It helps teams separate validated clinical activity from emerging preclinical signals and follow the sponsors building the next wave of theranostic assets.

  • Preclinical and transition assets
  • Sponsor and target visibility
  • Early signal monitoring
03
Module 03

Centre Activity Ranking AI

Centre Activity Ranking AI preview

AI-powered ranking of the most active centres by country using clinical-trial participation, maturity, target breadth and recency.

An AI ranking of the centres that matter most in each geography.

The scoring model combines trial participation, maturity of the programmes, target breadth, recent activity and curated centre consolidation. It is designed to support country prioritisation, KOL mapping, site selection, launch planning and business-development discussions.

  • Country-by-country centre ranking
  • Clinical activity and maturity signals
  • Useful for KOL and site strategy
04
Module 04

Trial Timeline Explorer

Trial Timeline Explorer preview

Visualize trial timelines across targets, molecules, sponsors, phase transitions and development milestones.

Follow each programme across time, from start dates to expected milestones.

The timeline module turns trial duration, status, phase, sponsor and target information into a visual chronology. It makes it easier to compare development speed, understand overlapping programmes and spot trials that may soon generate market-relevant data.

  • Trial chronology by target
  • Milestone and status visibility
  • Sponsor and phase context
05
Module 05

Maturity & Sponsor View

Maturity & Sponsor View preview

Understand trial maturity by sponsor, therapeutic target and development stage from preclinical to late-stage assets.

Understand who is early, who is late-stage and where maturity is concentrated.

Stacked maturity views show how programmes are distributed by sponsor, target or development stage. This helps distinguish exploratory pipelines from sponsors with late-stage concentration, and reveals whether a target is still emerging or already clinically mature.

  • Sponsor-stage comparison
  • Late-stage concentration
  • Target maturity distribution
06
Module 06

Centres & Trials Network

Centres & Trials Network preview

Map all centres associated with each trial and all trials attached to each centre, with mapped global activity.

Connect every trial to its centres, and every centre to its trial footprint.

This view links trials, countries and centres into a practical network. It shows which centres appear most frequently in public trial data, which trials are attached to each centre and where recruitment or site activity is geographically concentrated.

  • Trial-to-centre mapping
  • Centre-to-trial visibility
  • Country and site activity signals
07
Module 07

Opportunity Matrix / Competitive Density

Opportunity Matrix / Competitive Density AI preview

AI-scored density map combining opportunity signals, target maturity, active programmes, sponsor density and white-space detection.

A combined AI view of crowded spaces, white-space and development opportunity.

This module merges opportunity mapping with competitive-density scoring. It uses target activity, active programmes, sponsor density, late-stage assets and maturity bands to indicate where a segment is saturated, emerging, strategically open or potentially under-developed.

  • Crowded vs white-space detection
  • Target maturity and density signals
  • Monthly AI score refresh
08
Module 08

Sponsor–Target Heatmap

Sponsor–Target Heatmap preview

Identify which sponsors are active across targets and compare academic, industry, clinical and preclinical activity.

See which sponsors overlap on which targets, and where competition clusters.

The heatmap provides a sponsor-by-target view across clinical, preclinical, academic and industry activity. It helps BD teams identify concentration, overlap, focused niches and potential partnership or differentiation opportunities.

  • Sponsor-target overlap
  • Industry / academic segmentation
  • BD radar for competition
09
Module 09

Trial Cards List

Trial Cards List preview

Browse the research landscape by phase, target, pathology, country, sponsor, isotope and status in a fast visual format.

A fast visual scan of the full research landscape.

Trial cards provide an at-a-glance way to browse programmes by phase, target, country, sponsor, isotope, status and pathology. The format is useful for quickly reviewing many trials without losing the key strategic attributes of each programme.

  • Card-based exploration
  • Fast multi-filter review
  • Clear phase and status signals
AI
AI scoring models are recalculated monthly using the latest public clinical-trial registry data, curated clinical-trial sources, scientific publications, company disclosures and proprietary enrichment sources.

Turn complexity into clarity.

Request a personalised demo and see how Theranostix can support market access, portfolio strategy, BD and clinical-development planning.

Request a demo →
We are Theranostix

Our mission statement

Built from nuclear-medicine expertise and data intelligence, Theranostix exists to make the global theranostics market easier to read, earlier to understand and faster to act on.

Theranostix mission discussion
Medical insight × AI intelligence

Our mission

Theranostix

Theranostix helps pharma, biotech, investors and clinical leaders understand the fast-growing theranostics landscape. By combining clinical trial data, centre activity, target maturity, sponsor dynamics and competitive density, we transform fragmented information into strategic intelligence.

Co-founded with deep nuclear-medicine expertise, Theranostix was built to reflect the real clinical and scientific complexity of the field. Our goal is to make visible what matters: where trials are moving, which centres are leading, which targets are crowded, where opportunities remain and which programmes are gaining or losing momentum.

How it started

A field becoming strategic, but hard to read

Theranostix began with the conviction that theranostics is becoming one of the most important domains in precision oncology, but that its global development remains difficult to read.

As a nuclear-medicine physician, Dr Erard de Hemricourt experienced this complexity from within the field: the rise of radiopharmaceutical innovation, the growing role of molecular imaging, the need for expert centres and the strategic importance of understanding which trials, sponsors and targets are truly advancing.

Theranostix was created to bring clarity to that ecosystem. It combines medical insight and data intelligence to help decision-makers see the theranostics market earlier, more accurately and more strategically.

Theranostix team meeting
From field complexity to strategic clarity
Our spirit

Clinical truth, not generic market noise.

The platform is designed around the realities of theranostics: nuclear-medicine workflows, molecular imaging, radiopharmaceutical development, centre expertise and the difference between visible activity and true strategic momentum.

Clinical depth

Built to respect the scientific and medical complexity of theranostics, not to flatten it into generic oncology categories.

Data discipline

Registry data, sponsor activity, targets, centres and milestones are consolidated into decision-ready views.

Strategic clarity

Our purpose is to reveal what is moving, who is leading and where development opportunities remain open.

Request a demo

See how Theranostix can support your strategy.

Tell us who you are, what part of the theranostics landscape you need to understand, and which modules matter most for your team. We will use this information to prepare a focused demo.

1
Personalised walkthrough
Focused on your therapeutic area, geography, sponsor landscape or BD question.
2
Clinical and preclinical intelligence
Built for pharma, biotech, investors, clinical leaders and industrial strategy teams.
3
Direct contact
Your request is sent straight to our team at contact@theranostix.io.

Book a private demo

Complete the form below. The send button opens a prepared email addressed to Theranostix.

Your request is sent securely to our team. We usually reply within one business day.
← Back to site
Conditions of use

Terms & Conditions

Last updated: 1 January 2026
01

Acceptance

By continuing to browse and use this website and the Theranostix tool, you agree to be bound by these terms of use. If you disagree with any part of them, please do not use the site. “Esperity bv”, “we” or “us” refers to the owner of the website, whose registered office is Bd Brand Whitlock 108, 1200 Woluwe-Saint-Lambert, Brussels, Belgium; company registration number 0848.466.027. “You” refers to the user of the website.

02

Use of the platform

The content of these pages is for your general information and use only, and is subject to change without notice. Access to the Theranostix module is restricted to authorised partners holding a valid access code; you agree not to share your credentials and not to extract or systematically reuse the curated intelligence.

03

No warranty

Neither we nor any third party provide any warranty as to the accuracy, timeliness, performance, completeness or suitability of the information offered, for any particular purpose. You acknowledge that such material may contain inaccuracies, and we exclude liability for them to the fullest extent permitted by law. Your use of the information is entirely at your own risk.

04

No medical advice

The information and AI scores are provided for decision-support only and do not constitute medical advice. They do not replace clinical judgement or consultation of official sources.

05

Intellectual property

This website contains material owned by or licensed to us, including its design, layout, look, appearance, graphics, analytics and scoring. Reproduction is prohibited other than in accordance with the copyright notice. Trademarks not owned by us are acknowledged. Unauthorised use may give rise to a claim for damages and/or be a criminal offence.

06

External links

From time to time the site may include links to other websites, provided for your convenience. They do not signify endorsement, and we have no responsibility for the content of linked sites.

07

Governing law

Your use of this website, and any dispute arising from it, is subject to the laws of Belgium.

← Back to site
Data protection · GDPR

Privacy Policy

Last update: June 2026
01

What we collect

Theranostix is a restricted-access professional tool. We collect only the minimum required to grant and secure access: a professional email address and an access code issued to your organisation.

02

What we do NOT collect

We do not collect, host or process any patient, medical or health data through this portal. We build no user profiles and use no advertising or analytics trackers — only a strictly necessary session cookie.

Please sign in with a professional email only. Do not submit personal, patient or health information through this site.

03

Controller & legal basis

Data controller: Esperity bv, Bd Brand Whitlock 108, 1200 Woluwe-Saint-Lambert, Brussels, Belgium (company no. 0848.466.027). Processing is based on performance of the access contract and our legitimate interest in securing the service. Anti-abuse protection is provided via Cloudflare Turnstile.

04

Processors

Limited data may be processed by our technical providers: OVH (hosting, EU); Lovable / Supabase (authentication, data API); Cloudflare Turnstile (anti-bot). Any transfer outside the EU is covered by Standard Contractual Clauses.

← Back to site
Legal notice

General Conditions

Last updated: 1 January 2026
01

Publisher

Theranostix is published by Esperity bv, Bd Brand Whitlock 108, 1200 Woluwe-Saint-Lambert, Brussels, Belgium. Company registration number 0848.466.027; VAT BE0848466027. Contact: contact@theranostix.io. Publication director: Mitchell Silva.

02

Hosting

Website and static files: OVH SAS, 2 rue Kellermann, 59100 Roubaix, France. Application services (authentication, data API): Lovable / Supabase.

03

Data sources

Theranostix relies on public registries (ClinicalTrials.gov — public domain; CTIS — subject to EMA terms), scientific literature, company disclosures and proprietary enrichment.

04

Intellectual property

The structure, design, analytics and scoring of Theranostix are the protected property of Esperity bv. Any reproduction or systematic reuse without authorisation is prohibited.

05

Governing law

These conditions are governed by Belgian law.